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ABSTRACT 
Endocannabinoids are natural bioactive lipids which cause activation of cannabinoid 
receptors CB1 and CB2; and play an important role in numerous physiological and 
pathological conditions. However, endogenous lipids are rapidly hydrolyzed by fatty acid 
amide hydrolase (FAAH) and the monoacylglyceride lipase (MGL), the so called 
endocannabinoid degrading enzymes. Hence, the beneficial effects related to activation of 
cannabinoid receptors by endocannabinoids remains shorter. One potential approach to 
maintain levels of endocannabinoids is to block the endocannabinoid degrading enzymes 
by means of developing FAAH and/or MGL inhibitors.  
By means of mutagenesis and X-ray structures, it is well established that both FAAH and 
MGL contain serine residue (for FAAH: Ser
241
-Ser
217
-Lys
142
 while for MGL: Ser
122
-Asp
239
-
His
269
) in their active sites. Thus, both enzymes belong to the serine hydrolase family. 
Hence, the earlier development related to FAAH and MGL inhibitors were focused on more 
activated substrates analogues and via modification of known serine hydrolase inhibitors.   
 At present, a growing number of potent inhibitors have been developed in recent years; 
some selective to either of the enzymes and others exhibiting dual inhibition. 3,4-
disubstituted 1,2,5-thiadiazole carbamates have been shown in recent studies to be potent 
and selective inhibitors of lysosomal acid lipase (LAL), the enzyme responsible for the 
Niemann-Pick type C disease (NPC). Since both FAAH and MGL belong to the same 
serine hydrolase superfamily as LAL and have same kind of mechanism of inhibition, we 
thought to screen these analogues against both FAAH and MGL.  
In this study, we developed several 3,4-disubstituted 1,2,5-thiadiazole based carbamates 
and other analogues such as esters and sulfonate. Several of these analogues were 
synthesized as per the literature procedure. In vitro studies were carried out to determine 
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inhibitory activities of these compounds against both hrFAAH and hrMGL. The thiadiazole 
based carbamates, esters and sulfonate were synthesized and tested for inhibitory activities 
towards hrFAAH and hrMGL. The carbamates, in general, were observed to show 
inhibitory activities mainly towards hrFAAH while inhibitory activities were < 50% in 
cases where inhibitions were observed towards hrMGL with the exception of the compound 
68l and 68m. The compounds 68d, 68b, 68k and 68c were observed to be the most potent 
with IC50 values 17 nM, 32 nM, 78 nM and 155 nM respectively. The compounds 68a and 
68c were found to selectively inhibit hrFAAH with IC50 values < 0.5 µM. The compound 
68l was the only thiadiazole based carbamate, based on the results available, found to 
modestly inhibit hrMGL (IC50 = 3.85 µM). No inhibitory activities were observed with the 
thiadiazole based esters as well as the sulfonate and as such were not active against either 
of the enzymes. 
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ABBREVIATIONS 
 
2-AG: 2-arachidonoylglycerol 
2-AGE: 2-arachidonylglyceryl ether 
ABHD12: α/β-Hydrolase domain 12 
ABHD6: α/β-Hydrolase domain 6 
AChE: Acetyl choline esterase 
AEA: N-arachidonoylethanolamide 
cAMP: Cyclic adenosine monophosphate 
CB1: Cannabinoid receptor 1 
CB2: Cannabinoid receptor 2 
CBD: Cannabidiol 
CBR: Cannabinoid receptor 
CNS: Central nervous system 
DAGL: Diacylglycerol lipase 
DCC: Dicyclohexylcarbodiimide 
DCM: Dichloromethane 
DIPEA: N, N-diisopropylethylamine 
FAAH: Fatty acid amide hydrolase 
hFAAH: human fatty acid amide hydrolase 
hrFAAH: human recombinant fatty acid amide hydrolase 
hMGL: human monoacylglyceride lipase 
hrMGL: human recombinant monoacylglyceride lipase 
Ki: Inhibition constant 
LAL: Lysosomal acid lipase 
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MAFP: Methyl arachidonyl fluorophosphonate 
mMGL: Mouse monoacylglyceride lipase 
NAAA: N-acylethanolamine-hydrolyzing acid amidase 
NPC: Niemann-Pick type C disease  
PMSF: Phenylmethylsulfonylfluoride 
SAR: Structure-activity relationship 
THC: Δ9-Tetrahydrocannabinol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
TABLE OF CONTENTS 
Abstract ...………………………………………………………….……………………….2 
Acknowledgement ………………………….…………………...…………………………4 
Abbreviations ........................................................................................................................5 
1. Literature Review: Recent development of FAAH/MGL inhibitors…............................9 
1.1 Introduction ……………………………………............................................................9 
1.2 Fatty Acid Amide Hydrolase …………………………………….................................11 
1.3 Monoacylglyceride Lipase……………..........................................................................12 
1.4 Therapeutic potentials of FAAH and MGL inhibitors…………………….………...…14 
1.4.1 Recent development of FAAH Inhibitors................................................................... 15 
1.4.1.1 α- keto heterocycle based FAAH inhibitors……….…………..………................... 15 
1.4.1.2 Carbamate-based FAAH inhibitors……………………………………….............. 17 
1.4.1.3 Urea-based FAAH inhibitors………………........................................................... 21 
1.4.1.4 Boronic acid-based FAAH inhibitors……………………...................................... 23 
1.4.1.5 Other classes of FAAH inhibitors………………………………........................... 25 
1.4.2 Recent development in MGL inhibitors……………………………………..............28 
1.4.2.1 Urea-based MGL inhibitors……………………………......................................... 29 
1.4.2.2 Carbamate-based MGL inhibitors…………………….............................................29 
1.4.2.3 Pristimerin………………………………………………………………………….31 
1.4.3 Recent development of Dual FAAH and MGL inhibitors………………………..…32 
1.5 Current scenario of FAAH and MGL inhibitors........................................................... 33 
2 Experimental Part: Synthesis of thiadiazole based carbamates and other analogues....... 34 
2.1 Introduction…………………………………………………………………………….34 
2.2 Chemistry........................................................................................................................34 
8 
 
2.3 Experimental Procedure……………………………………………………….…….....37 
2.4 Results and Discussion................................................................................................... 59 
2.5 Conclusion………………………………….................................................................. 62 
REFERENCES ................................................................................................................... 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
1 LITERATURE REVIEW: Recent development of 
FAAH/MGL inhibitors 
1.1 INTRODUCTION  
The effects of cannabinoids are mainly mediated by two G-protein coupled receptors, the 
cannabinoid receptors CB1 and CB2, which are activated by bioactive endogenous 
cannabinoids called endocannabinoids (Figure 1). Endocannabinoids are very significant in 
bioregulation and studies have shown their roles in inflammation, insulin sensitivity, and 
fat and energy metabolism. They also play a key role in memory, mood, brain reward 
systems, drug addiction, and metabolic processes, such as lipolysis, glucose metabolism, 
and energy balance (Le Foll et al, 2005).  
At present two endocannabinoids namely: N-arachidonoylethanolamine (AEA) and 2-
arachidonoylglycerol (2-AG) are of prime focus. The beneficial effects of both AEA and 2-
AG related to activation of cannabinoid receptors are short due to immediate degradation 
by enzymes. Fatty acid amide hydrolase (FAAH) is found to be the main enzyme 
responsible for the degradation of AEA while monoacylglycerol lipase (MGL) along with 
two additional hydrolases namely α/β-Hydrolase Domain 6 (ABHD6) and α/β-Hydrolase 
Domain 12 (ABHD12) are found to be responsible for the degradation of 2-AG (Paunescu 
et al, 2011). This hydrolysis procedure serves as means of endocannabinoids inactivation or 
clearance from the system. 
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Figure 1. The Endocannabinoid system  
In order to achieve levels of both AEA and 2-AG, blockage of FAAH and MGL is 
essential. Hence, the development of inhibitors for FAAH, MGL, ABHD6 and ABHD12 
are under progress. At present, numerous scaffolds acting as potent FAAH inhibitors have 
been disclosed among which some are in preclinical/clinical stage. Recently, several 
examples of MGL inhibitors are reported but the wait for clinical candidate is still on. 
Furthermore, only one selective ABHD6 inhibitor has been identified while no selective 
ABHD12 inhibitor is reported.   
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1.2 FATTY ACID AMIDE HYDROLASE (FAAH) 
Fatty acid amide hydrolase (FAAH) is a membrane-bound enzyme, which belongs to the 
family of amidase signature (AS). The enzyme is present in large principal neurons, such as 
the pyramidal cells of the cerebral cortex, the pyramidal cells of the hippocampus, the 
Purkinje cells of the cerebellar cortex and the mitral cells of the olfactory bulb. 
Immunocytochemical analysis of these brain regions revealed a complementary pattern of 
FAAH and CB1 expression with CB1 immunoreactivity occurring in fibers surrounding 
FAAH-immunoreactive cell bodies and/or dendrites (Egertova et. al., 2003). This 
complementary distribution suggests that FAAH closely controls the duration of 
cannabinoid effects, although there are sites where this association does not occur, such as 
the outflow nuclei of basal ganglia.  
FAAH has been cloned from four mammalian species: man, rat, mouse and pig. It has been 
shown to be a 65kDa protein and in all cases. FAAH is 579 amino acids in length, of which 
73% are identical in the four species. The degree of homology increases to 90% in the so 
called “amidase signature” domain from amino acid 215-257 (Di Marzo et. al.). X-ray 
crystallographic study of the enzyme showed the presence of several domains implicated in 
distinct functions; a large domain composed by hydrophobic and basic residues covers the 
active site and allows the enzyme to anchor to the membrane, a channel responsible for the 
entry of the substrate into the active site lies near the hydrophobic core and the presence of 
the hydrophobic cavity. Also there is the presence of cytosolic part which is found to 
interact with the polar head of the substrate and is connected to the cytosol. The active site 
is also able to accommodate a water molecule to hydrolyze the acyl-enzyme complex 
(Feledziak et. al., 2012). 
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 The enzyme possesses the amino acids Ser-Ser-Lys at its catalytic site which enable the 
FAAH to hydrolyze a number of endogenous bioactive lipids. McKinney and Cravatt 
proposed a catalytic mechanism through the formation of a tetrahedral intermediate. 
Uncharged Lys-
142
 initiates catalysis by accepting a proton from Ser-
217
, which in turns 
deprotonates Ser-
241
 nucleophile to facilitate attack on the substrate carbonyl (McKinney 
and Cravatt, 2005). 
FAAH, known for being the main AEA degrading enzyme also hydrolyzes and thus 
regulates levels of other bioactive lipids. Endogenous bioactive lipids regulated by FAAH 
include AEA, N-palmitoyl ethanolamine, oleamide, N-arachidonoyl glycine etc. (Giang and 
Cravatt, 1997). 
1.3 MONOACYLGLYCERIDE LIPASE (MGL) 
Monoacylglyceride lipase (MGL) is located mainly in the hippocampus, cortex, cerebellum 
and anterior thalamus, with moderate expression in the extended amygdala, including the 
shell of the nucleus accumbens (Dinh et. al., 2002). MGL is also present in the adipose 
tissue. It is a 33kDa enzyme and is the main enzyme responsible for the regulation of the 
endogenous cannabinoid, 2-arachidonyl glycerol (2-AG). Unlike AEA, 2-arachidonyl 
glycerol acts as a full agonist at both CB1 and CB2 cannabinoid receptors. 2-AG elicits a 
wide range of beneficial properties, among which are analgesic, anti-inflammatory, 
immunomodulating, neuro-protective and hypotensive effects, as well as the ability to 
inhibit the growth of prostate and breast cancer cells (Labar et. al. 2010a). 
The crystal structure of human MGL was reported by Labar et. al. (2010), and also Schalk-
Hihi et. al. (2011). The crystal structure was solved at 2.2 Ǻ and 1.5 Ǻ resolutions by X-ray 
diffraction respectively. MGL was shown as a dimer with two molecules per asymmetric 
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unit, with the two monomers in contact with each other by a surface of 884 Ǻ2 which 
represents about 7% of the total surface of a monomer. The dimeric form of the hMGL was 
also confirmed by a mass spectrometry studies. The catalytic site entries on both monomers 
were shown to face the same direction and are thus properly oriented to interact with the 
membrane in order to recruit the substrates. The crystal structure of hMGL was also shown 
to be made up of secondary structures, and have been shown to belong to the α/β-hydrolase 
superfamily. The central β-sheet, constituted of seven parallel and one antiparallel strands 
and is surrounded by six α helices. Striking feature of MGL is the unique cap domain, 
which varies much more among the members of this superfamily, and covers the 
structurally conserved β-sheet and the active site. Buried below the cap is the catalytic 
triad, closely superimposed on that of other hydrolases and haloperoxidases, and made up 
of residues Ser
122
, Asp
239
 and His
269
. The tridimensional structure thus provides the first 
direct evidence of the identity of this catalytic triad. The Ser
122
 is located in the GXSXG 
consensus sequence, between helix α-3 and strand β-5, in the so-called “nucleophilic 
elbow” sharp turn found within this superfamily. The oxyanion hole is constituted by 
backbone NH from Ala
51
 and Met
123
 and stabilizes the tetrahedral anionic intermediate 
during hydrolysis. Also, Labar et. al. (2010) reported the crystal structure of MGL. They 
identified Cys
201
 as the crucial residue in MGL inhibition by N-arachidonylmaleimide (52), 
a sulfhydryl-reactive compound developed by Saario et. al. (2005). The presence of four 
cysteine residues at the active site had also been reported to interact with some enzyme 
inhibitors (Saario et. al. 2005). They showed the presence of a highly hydrophobic cavity at 
the surface of the enzyme which leads to the active site of the enzyme and interacts with the 
lipophilic chain of the substrate, and also a lid at the entrance of the channel which allows 
the enzyme to interact with the cell membrane. Closer to the active site is the presence of a 
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hydrophilic pocket which appears to accommodate the substrate’s glycerol moiety.  This 
alcohol-binding pocket contains three amino acid residues; Ala
51
, His
121
 and Tyr
194
 (Labar 
et. al. 2010b). These residues have been shown to be very important in substrate 
recognition and thus are potential targets for enzyme inhibitors. Two non-catalytic cysteine 
residues Cys
201
 and Cys
242
 present in the vicinity of the active site have also been suggested 
to be potential site for potent enzyme inhibition.  
1.4 THERAPEUTIC POTENTIALS OF ENDOCANNABINOID-
HYDROLYZING ENZYME INHIBITORS 
Inhibition of endocannabinoid-hydrolyzing enzymes increases the tissue levels of 
endocannabinoids in the periphery as well as in the central nervous system, thus 
augmenting the endocannabinoid signaling and retention of the beneficial effects of 
cannabinoid receptor activation. This mechanism also avoids the undesirable psychoactive 
and CNS related side effects often associated with exogenous ligand of CB1 and CB2 
receptors. 
Due to the several benefits derived from cannabinoids, several strategies had been devised 
to augment the endocannabinoid signaling. One of such approaches had been the synthesis 
of cannabinoids in recent years. The technique in synthetic cannabinoids had advanced, but 
so far there have been few of such products which have been clinically approved for usage 
and are being marketed. These synthetic cannabinoids serve as either agonist or antagonist 
to the cannabinoid receptors (CB1 and CB2). They are been employed to reduce pain due 
cancer, multiple sclerosis, and inflammation and have also been used to control weight gain 
in the treatment of obesity. Some examples of the synthetic cannabinoids include 
Nabiximols (Sativex), derived from cannabis plants and have been formulated as an 
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oromucosal spray which is administered by spraying into the mouth, Dronalinol (Marinol), 
a cannabinoid receptor agonist, a medication is used to treat nausea and vomiting caused by 
cancer chemotherapy and also to treat loss of appetite and weight loss in patients infected 
with HIV, Rimonabant, the first selective CB1 receptor blocker to be approved for use 
anywhere in the world, the CB1 selective receptor agonists, (R)-(+)-methanandamide and 
arachidonoyl-2’-chloroethylamide (ACEA) (Pacher et. al. 2006). 
1.4.1 RECENT DEVELOPMENT OF FAAH INHIBITORS 
FAAH knock-out showed increase in the levels of AEA (10-14 folds) with decrease pain 
and memory loss. Hence, the inhibitors of FAAH are viewed as useful approach to achieve 
auspicious outcome related to cannabinoid receptors. The same effects were observed by 
chemical inhibition of FAAH which has prompted many researchers to explore the 
development of selective and potent FAAH inhibitors. With the help of different animal 
disease models, the inhibitors of FAAH are found to be involved in analgesic, 
antidepressant-like effect, anxiolytic-like effect, as well as neuro and immunomodulators in 
the immune system. Till date diverse classes of FAAH inhibitors were reported and are 
summarized briefly as follows: 
1.4.1.1 α-Keto heterocycles based FAAH inhibitors 
The first generation inhibitors were based on the substrates oleoylethanolamide, palmitoyl-
ethanolamide and anandamide. The mechanism of inhibition was based on the attack of the 
nucleophilic Ser
214
 at FAAH’s active site on the electrophilic carbonyl of the inhibitor. The 
significant feature of this inhibition was that it is reversible. Trifluoromethyl ketones 
bearing analogues were investigated (Boger et. al. 2000a) for inhibition against FAAH. 
They showed that the trifluoromethyl ketone was far more potent compared to the methyl 
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ketone analogue (Ki = 0.082 µM and Ki > 100 µM respectively) due to the presence of 
electrophilic trifluoromethyl group. Thus, the electrophilic carbonyl forms enzyme 
stabilized reversible covalent hemiketal or hemithioketals with the enzyme’s catalytic 
nucleophile. Replacing the CF3 moiety with α-N4-oxazolopyridine provided inhibitors 
exemplified by 1 that are 10
2–103 times more potent than the corresponding trifluoromethyl 
ketone analogues (Boger et. al. 2000b). The problem with the earlier α-keto heterocycle 
inhibitors was that they were poorly selective over the serine hydrolase enzymes and they 
fail to demonstrate activity in vivo, as such they were poor drug candidates.  
Recently, advances had been made to improve both the potency and selectivity of the α-
keto heterocycle inhibitors. The replacement of the CF3 group by heterocycle and the long 
aliphatic chain with simplified phenylhexyl moiety resulted in the first highly potent and 
selective inhibitor OL-135 (2) of FAAH (Cravatt and Boger, 2005). Recently, a crystal 
structure of the inhibitor 2 in complex with hFAAH was reported confirming the mode of 
inhibition of FAAH via a reversible hemiketal formation with the nucleophilic ser
241
. 
Modification to 2 by Leung et. al. (2005), by fusing the heterocyclic rings (oxazole and 
piperidine) together generated the compound 3 which was shown to be more potent 
compared to 2. In the structure activity studies of the various analogues synthesized, they 
established that potency of the α-keto analogues increases in a parabolic fashion with 
regards the alkyl chain and optimal activity was achieved when n = 6 (n is number of CH2 
in the alkyl group), however, selectivity of the compounds increases with increasing length 
of the alkyl chain).  Further studies were carried out on 2 by Janssen Pharmaceuticals in 
2007. They replaced the phenylhexyl moiety with several alkylated or acylated N-
substituted 4-piperidines or 4-propylpiperidines. They published two patents containing the 
SAR studies and compound 4 was shown to be the most potent. The compounds also 
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showed improved solubility relative to 2. An optimization of 2 was recently carried out by 
Ezzili et. al. (2011), making a conformational constraint to the C2 acyl side chain 
generating compound 5. Two enantiomers were generated and shown that only one of 
them, the (S) enantiomer was a potent inhibitor in compared to 2. In vivo studies showed 
the compound possesses analgesic activity and has since been patented. Also, based on α- 
N4-oxazolo moiety, Rusch et. al. (2012) synthesized several analogues containing sulfone 
moiety while maintain the aliphatic chain moiety of the first generation inhibitors, 
Compound 6 was shown to be the most potent. They also showed that the compound was 
very selective to FAAH over the other serine hydrolases tested. 
 
Figure 2. α-Keto heterocycle based inhibitors 
 
1.4.1.2 Carbamate-based FAAH inhibitors 
 Carbamate-based inhibitors had been synthesized and used to inhibit serine proteases in an 
irreversible manner. The first attempt to synthesize carbamate-based inhibitors was carried 
out by Mor et. al. in 2004. They made a modification to the known AChE inhibitor 7, 
generating O-aryl carbamate URB524 (8) which was later optimized to the URB597 (9), a 
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compound which has been widely used as a pharmacological tool, both in vitro and in vivo. 
Following observations that the compound was prone to metabolic oxidation by 
hydroxylation at the C4 position, further optimization was carried out by Dasse et. al. 
(2008) on the compound. They blocked the C4 position with a dimethyl at the C4 position, 
thereby stabilizing the compound. It has also been shown that compound 9, though being 
selective towards FAAH also has many off-targets including carboxylesterases. Tarzia et. 
al. (2006) then refined the structure with the addition of electron donating substituents and 
produced a second generation series of O-arylcarbamate inhibitors (10, 11) demonstrating 
greater plasma stability, prolonged half lives in vivo, and decreased activity toward liver 
carboxylesterases in comparison to 9. It was found that addition of small electron-donating 
substituents at conjugated positions of the O-aryl moiety increased the overall hydrolytic 
stability of the carbamate group without affecting FAAH inhibitory potency. Recently, 
Clapper et. al. (2010) developed compound 12, a derivative of 10 and showed that it 
selectively inhibits FAAH in the periphery over the CNS. O-Phenyl carbamates had also 
been studied earlier on in the development of carbamate-based FAAH inhibitors. 
Researchers at Astellas Pharmaceuticals (2006) synthesized compound 13 and showed that 
it was a potent inhibitor of FAAH. Saario et. al. (2008) also developed the compound 14 
and showed that it was a very potent rFAAH inhibitor. Following the prospects of 
carbamates to inhibiting FAAH, the pharmaceutical firm, Sanofi-Aventis studied numerous 
N- and O- substituents including piperazinyl, alkyl, azetidinyl and thioazoyl and has since 
published several patents. One of such compounds is SA-47 (15) which had been shown to 
be a highly selective FAAH inhibitor. Recently, Niphakis et. al. (2012) synthesized O-
hydroxyacetamide carbamate SA-57 (16) and showed that the compound showed high 
potency and selectively inhibits FAAH at low concentrations and additional activity against 
19 
 
MGL and ABHD6 at higher concentrations. Researchers at Ironwood Pharmaceuticals 
(2012) developed series of compounds comprising oxazole ketone and carbamate moiety, 
the N-alkylated indole-3-ketoamides exemplified by compound 17. They claimed in the 
patent that the compounds are potent and selective hFAAH inhibitors both in vitro and in 
vivo. Another class of arylpiperazine carbamate-based FAAH inhibitors was recently 
developed by Butini et. al. (2013). They modified the compound ST-3913 (18) by 
appending a piperazine ring on the 1-phenylpyrrole system, which they had developed 
earlier on and had identified it as a potent and selective FAAH inhibitor (Butini et. al. 
2012). Series of derivatives were developed and compounds 19 and 20 identified as potent, 
reversible and non-competitive FAAH inhibitors.  
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Figure 3. Carbamate-based FAAH inhibitors 
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1.4.1.3 Urea-based FAAH inhibitors 
Urea-based FAAH inhibitors are irreversible inhibitors that form covalent tight binding 
with the catalytic Ser
241
 residue within the active site of the FAAH enzyme unlike the α-
keto heterocycles which are reversible inhibitors believed to form a hemiacetal bond with 
the catalytic serine residue. Urea functional groups have a high resistance to both chemical 
and biological hydrolysis as not found suitable as FAAH inhibitors by earlier researchers. 
However, with the with the potential of adjacent leaving groups capable of making the urea 
carbonyl group more reactive, much attention and effort had been channeled into 
developing urea-based FAAH inhibitors over the years. One of the first examples of an 
electrophilic urea-based FAAH inhibitor was the tetrazole-based compound LY-2183240 
(21) which was originally described as an AEA transport inhibitor. However, it was later 
found to be a potent inhibitor of FAAH. Mass spectral studies of the enzyme-inhibitor 
adduct verified that the inhibition was due to covalent modification of the catalytic Ser
241
 in 
a binding mode similar to that of the carbamates. Since then, much progress had been made 
in that area. Janssen Pharmaceuticals in 2006, developed series of piperazinyl urea 
compounds exemplified by JNJ-1661010 (22) which exhibited both in vitro and in vivo 
activities. The breakthrough in the development of urea based inhibitors was with the 
discovery of the compounds PF-622 (23) and PF-750 (24) by Pfizer in the late 2000s. The 
compounds were shown to be active and selective inhibitors of FAAH. Later on the same 
company developed another series of piperidinyl urea scaffold which showed greater 
potency and excellent selectivity towards FAAH. The most common and well known of 
this series is PF-3845 (25). In their studies, Pfizer showed that the urea series were more 
potent compared to the most common carbamate 4. Further improvements on 25 (Pfizer, 
2011) resulted in PF-04457845 (26). Being a most potent and selective inhibitor of FAAH, 
22 
 
the compound 26 was considered to be an ideal drug candidate which has reached phase II 
preclinical trial. However, due to recent disappointment related to the treatment of arthritis 
patient, the compound was found to be ineffective. Janssen Pharmaceuticals also recently 
(2010) developed azetidinyl urea compounds exemplified by 27. The compound was shown 
to be very potent against both rFAAH and hFAAH, according to their patent.  Tichenor et. 
al. (2012) studied the structure activity relationships for a series of heteroaryl urea 
inhibitors of FAAH as well as the mutagenicity of the arylamine leaving group. They 
developed series of monocyclic heteroaryl and fused bicyclic heteroaryl urea derivatives. 
They observed that compound 28 to be the most potent among the series of the monocyclic 
heteroaryl urea compounds, whereas compound 29 was the most potent among the fused 
bicyclic series. In their findings, they showed that variety of unsubstituted five and six-
membered heteroaryl ureas were potent inhibitors of FAAH, and were not likely to be 
mutagenic. However, the fused bicyclic heteroaryl amines were much more likely to be 
mutagenic, but several analogs related to the benzo[d]isoxazol-3-ylamine and imidazo[1,2-
α]pyridin-3-ylamine were potent FAAH inhibitors and their metabolites not likely to be 
mutagenic. Also Kono et. al. (2013) studied the SARs of series of piperazine ureas as 
potent FAAH inhibitors. They carried out an optimization study of their lead compound 30 
which developed earlier on to improve its metabolism and pharmacokinetics profile as well 
as in vitro potency. They observed from their SARs studies that the removal of the benzene 
ring in the benzoisoxazole moiety improved the solubility. Also replacement of the 
thiadiazole ring with thiazole led to increase of the FAAH inhibitory activity and a further 
improvement of solubility and introduction of fluoro group on the phenyl ring enhanced 
activity along with increase of drug exposure and brain permeability. The compound 31 
was shown to be very potent and with both in vitro and in vivo activities.  
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Figure 4. Urea-based FAAH inhibitors 
1.4.1.4 Boronic acid-based FAAH inhibitors 
The importance of the carbonyl functional group have been cited and shown to involve in 
covalent bond formation with Ser
214
 at FAAH active site. Boronic acid has also been 
studied due to its electrophilic functional group as a FAAH inhibitor. The functional group 
had previously been shown to be important in the inhibition of serine proteases in a 
reversible manner. It has been shown to form a reversible tetrahedral intermediate with the 
serine nucleophile. Infinity Pharmaceuticals published in 2008 the first arylboronic acid 
FAAH inhibitor 32. Meanwhile, Minkkilä et. al. (2008) also published another arylboronic 
acid FAAH inhibitor 33. Both compounds were shown to be potent and reversible FAAH 
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inhibitors.  Infinity Pharmaceuticals thereafter, did further studies based on 32 with various 
substituted aryl-boronic acids exemplified by 34 and tetrahydropyridine based boronic acid, 
35, both showing potency and then published two patents in 2009 (Behnke et. al. 2009) and 
2010 (Castro et. al. 2010). Recently, a patent showing the SARs of various boronic acid 
derivatives including carbamates, esters and α-keto analogues, was published (Adams et. al. 
2012). The various groups were exemplified with compounds 36, 37, 38 and 39 for the 
boronic acid, carbamates, esters and the α-keto derivatives respectively, with all showing 
inhibitory activities against hFAAH. 
 
Figure 5. Boronic acid-based FAAH inhibitors 
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1.4.1.5 Other classes of FAAH inhibitors 
Benzofurans 
Several other classes of functional groups have been developed and shown to be potent 
FAAH inhibitors. Gustin et. al. (2011) synthesized series of 4-[2-benzofuran]2-yl-
pyrimidines substituted with a pyrrolidine, piperidine or homopiperidine bearing a methyl-
ketobenzimidazole unit and showed through their SARs studies and co-crystallography 
with rat FAAH that the compounds 40, 41 and 42 were non-covalent FAAH inhibitors. 
Tetrahydropyridopyridine 
Recently, new series of non-carbonyl FAAH inhibitors have been synthesized and of which 
compound RN-450 (43) have been shown to be the most potent (Gowlugari et. al. 2012). 
The idea of developing these series was to avoid the electrophilic carbonyl in the previous 
classes of inhibitors discussed which covalently links the catalytic serine residue and hence 
has the potential of acylating other nucleophiles or serine hydrolases.  
Sulfonyl fluorides 
Sulfonyl fluorides have been known to inhibit esterases. Alapafuja et. al. (2012) recently 
identified sulfonyl fluorides as potent and selective FAAH inhibitors. Based on an earlier 
study where they found out that the sulfonyl fluorides were able to inhibit FAAH both in 
vitro and in vivo, they synthesized several sulfonyl fluoride analogs exemplified by AM-
3506 (44) and showed that the compounds exhibit high potency and also selectively inhibit 
rFAAH in an irreversible covalent manner.  
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Synthetic analogues of natural products 
Macamides are natural products that a bear structural similarity to AEA. Wu et. al. (2013) 
synthesized some synthetic analogues of macamides, unique series of non-polar, long-chain 
fatty acid N-benzylamides obtained from the plant maca (Lepidium meyenii), which is 
widely used as a food supplement. Of the analogues synthesized, they found out that only 
five were active as FAAH inhibitors in sub-micromolar range with the most potent being 
compound 45 with almost 100% inhibition. They evaluated three compounds in a pre-
incubation time study and found out that two of the analogues were not reversible inhibitors 
of FAAH whereas the third 45, the most potent, a carbamate structurally related to 
macamides, was an irreversible inhibitor of FAAH.  
Amides 
Recently, Advinus therapeutics from India (2013) published a patent on amide-based 
compounds as potent FAAH inhibitors exemplified by compound 46, an analogue of PF-
04457845 (26) with an amino group on the pyrimidine ring. The compounds were shown to 
exhibit inhibitory activity both in vitro and in vivo on hFAAH. 
β-Lactams 
β-Lactams have also been identified as a class of FAAH inhibitors that exhibited good 
potency in a reversible manner 47. This class of β-lactams is rather interesting since β-
lactams are known to typically acylate nucleophilic serine residues to form stable acyl-
enzyme intermediates with serine hydrolases in an irreversible manner (Urbach et. al. 
2008). 
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Oxime carbamates 
Oxime carbamates have been reported as novel competitive reversible inhibitors of FAAH. 
Exemplified by 48, the compound has been shown to exhibit in vivo activity in an animal 
pain model. Other types of oxime carbamates have also been shown to exhibit non-
competitive but reversible FAAH inhibition. The compound 49, exhibited potency and 
selectivity for FAAH over the other enzymes and the endocannabinoid receptors (Sit et. al. 
2010). Oxime carbamates have been shown to have an enhanced FAAH activity over the 
simple carbamates and the enhanced activity was mainly due to the alkoxy chain length. 
 
Figure 6. Other classes of FAAH Inhibitors 
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1.4.2 RECENT DEVELOPMENT OF MGL INHIBITORS 
Several potent inhibitors of MGL had been developed successfully by pharmaceutical 
companies and academic research groups. Among which ureas, carbamates, terpenoids and 
α-keto oxadiazole derivatives are reported as MGL inhibitors.  
1.4.2.1 Urea-based MGL inhibitors 
The first most potent MGL inhibitor (52) was developed by Saario et. al. (2005). They 
developed several N-ethylmaleimide analogs revealed that analogs with bulky hydrophobic 
N-substitution were more potent inhibitors than the hydrophilic or the less bulky analogs. 
They showed that the analogue N-arachidonyl maleimide (NAM) (52) was the most potent 
among the series synthesized. Since then, several classes of MGL inhibitors had been 
developed. 
In 2008, Sanofi-Aventis published the first ever urea-based MGL inhibitors. They 
developed several piperazine, triazole and triazolopyridine urea compounds exemplified by 
compound 53. They showed that the compounds were potent mMGL inhibitors with IC50 
values in the nanomolar range. Selectivity between MGL and FAAH was an issue with the 
series as some of the compounds selectively inhibit MGL whereas others exhibited dual 
MGL and FAAH inhibition. Later on, Makriyannis et. al. (2009) developed another type of 
urea-based inhibitors bearing an iso-thiocyanate function group exemplified by compound 
54. The series were shown to exhibit potent hMGL inhibition. Recently, Morera et. al. 
(2012a) developed a new potent and selective inhibitor of hMGL, 55. The triazolopyridine 
based urea compound was shown to exhibit spectacular increase in both potency and 
selectivity for MGL with the addition of steric hindrance with the bulkier diphenylmethyl 
substituent, and also resulted in a potency for the MGL by a factor of ten (10) whilst 
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substantially decreasing FAAH inhibitory activity, thus resulting in a three order of 
magnitude selectivity, and being 70 times more potent compared with JZL184 (56) in the 
same assay conditions. Through rapid dilution assay and DMPK studies the researchers 
showed that the compound 55 is an irreversible inhibitor of MGL.  
 
Figure 7. Urea-based MGL Inhibitors 
1.4.2.2 Carbamate-based MGL inhibitors 
Earlier work on development of potent MGL inhibitors was carried out by Tarzia et. al. 
(2003). They developed the compound URB602 (56), however, the compound lacked 
selectivity and inhibits FAAH with similar potency. In the course of the search for 
compounds capable of selectively inhibiting MGL, Cravatt et. al. (2010) screened their 
library of carbamates. They found some series of piperidinyl and piperazinyl carbamates 
which were able to selectively inhibit MGL. They observed that, as was the case with 
compound 55, bulkier groups (steric hindrance) were important to attain selectivity towards 
MGL. Based on this assumption, they developed the compound JZL 184 (57), a highly 
selective and efficacious MGL inhibitor. The compound was also shown to partially inhibit 
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FAAH following high-dosing and chronic treatment regimens, hence not selective enough. 
Recently, Chang et. al. (2012) identified inhibitors that show complete selectivity for MGL 
over FAAH, thus avoiding the potentially confounding effects of dual activation of 2-AG 
and AEA pathways in vivo. They developed a distinct class of carbamate inhibitors bearing 
a hexafluoroisopropanol leaving group exemplified by compound KML 29 (58). The 
compounds were shown to selectively inhibit MGL in vivo and showed no significant 
activity towards FAAH. In 2010, Janssen Pharmaceuticals published a patent on 
heteroaromatic and aromatic piperazinyl azetidinyl amides as potent MGL inhibitors. 
Exemplified by compound 69, these classes of compounds were shown to inhibit MGL 
both in vitro and in vivo and the researchers also claim that the compounds could be 
developed into drugs for the treatment of disorders or conditions affected by inhibiting 
MGL. Also, Sanofi in 2011 published another patent on hexafluoroisopropyl carbamate 
derivatives exemplified by compound 60. They claimed that their inventions have 
inhibitory activities with respect to MGL. And recently, Janssen Pharmaceuticals published 
two patents on diazetidinyl diamide (Connolly et. al. 2012) and amino-pyrrolidine azetidine 
diamides (Zhang et. al. 2012) respectively as inhibitors of MGL, claiming that the 
inventions are potent MGL inhibitors. Exemplified by compound 61, the compounds were 
shown to exhibit both in vitro and in vivo activities against rMGL.  
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Figure 14. Carbamate-based MGL Inhibitors 
1.4.2.3 Pristimerin 
Pristimerin (62) is a naturally occurring terpenoid that potentially inhibits MGL. It inhibits 
MGL in a rapid reversible and non-competitive manner (Alvin et. al. 2009). Pristimerin has 
been shown to significantly increase the levels of 2-AG in isolated rat neurons, thus 
indicating it inhibits endogenous MGL. Furthermore, the level of palmitoyl ethanolamide 
was not affected following Pristimerin administration suggesting it does not inhibits 
endogenous FAAH. 
 
Figure 8. Pristimerin 
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1.4.3 RECENT DEVELOPMENT OF DUAL FAAH/MGL INHIBITORS 
Dual FAAH and MGL inhibition have been shown to exhibit therapeutic potentials with the 
confounding effects of dual activation of 2-AG and AEA pathways in vivo. Long et. al. 
(2009) tried to develop dual FAAH and MGL inhibitors that were based on an electrophilic 
N-carbonyl piperidine/piperazine structural motif common to both the MGL inhibitor 
JZL184 (56) and the FAAH-selective inhibitors PF-622 (21) and PF-3845 (23). Series of 
analogues were synthesized and the compound JZL195 (63) was shown to inhibit both 
FAAH and MGL and also displayed high selectivity for FAAH and MGL in the nervous 
system, inhibiting only a single additional serine hydrolase target, ABHD6. Also recently, 
Morera et. al. (2012b) developed potent dual FAAH and MGL inhibitors 64a and 64b, 
bearing a benzotriazol-1-yl carboxamide scaffold. The compounds were shown to be very 
potent dual FAAH and MGL inhibitors with selectivity of 0.7 
 
Figure 9. Dual FAAH and MGL Inhibitors 
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1.5 CURRENT SCENARIO OF FAAH AND MGL INHIBITORS 
As shown above, several FAAH inhibitors are identified and have shown promising results 
in preclinical and early clinical trials. However, there are many hurdles in terms identifying 
the first suitable FAAH inhibitor as an ideal drug in terms of potency and selectivity 
towards other potential off-targets, reversibility versus irreversibility and efficacy towards 
both rat and human FAAH. In terms of development of MGL inhibitors, several groups 
have reported potent and selective inhibitors however it is too early to comment about 
utility of MGL inhibitors as a potential drug. 
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2 EXPERIMENTAL PART: SYNTHESIS OF 
THIADIAZOLE BASED CARBAMATES AND OTHER 
ANALOGUES 
2.1 INTRODUCTION 
Lysosomal acid lipase (LAL) has been recently identified as a potential therapeutic target 
for the Niemann-Pick type C disease (NPC). This enzyme is found in the lysosomes, where 
it breaks down fats (lipids) such as cholesteryl esters and triglycerides and employs a 
chymotrypsin-like hydrolysis mechanism involving a serine nucleophile, aspartic acid, and 
a histidine. LAL has been shown to be specifically inhibited by a variety of 3,4-
disubstituted thiadiazole carbamates (Rosenbaum et. al. 2010). As LAL belongs to same 
serine hydrolase family as FAAH and MGL and has the same catalytic triad as MGL (Ser-
Asp-His) we thought to modify it as a potential FAAH and/or MGL inhibitor. 
1,2,5-Thiadiazole, a five-membered heterocyclic ring is utilized in the development of 
drugs e.g. timolol, a nonselective β-adrenergic receptor blocker used for the treatment of 
hypertension, angina, tachycardia and glaucoma and xanomeline, a selective agonist of 
muscarinic acetylcholine receptor subtypes M1 and M4. Moreover, bioisosteric 
replacement of oxadiazole, oxazole and benzene by thiadiazole typically leads analogues 
with improved activities due to the sulfur atom which imparts improved liposolubility (Li 
et. al. 2013).  
2.2 CHEMISTRY 
The 1,2,5-thiadiazole carbamates with tertiary amino group were synthesized by the 
method described by Rosenbaum et. al. (2010). It follows a three step reaction to generate 
the final carbamate. In the first step, one of the halogens of the 3,4-dichlorothiadiazole (65) 
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is replaced by a nucleophile, a secondary amine (R1H). The product formed is isolated and 
purified and then the remaining chlorine atom is hydroxylated to afford the corresponding 
alcohol derivative (67) in the second step and is then isolated and purified. In the final step 
the 67 is converted to activated potassium salt using potassium tert-butoxide (KOtBu) in 
THF and then coupled to a carbamoyl chloride (R2COCl) to generate the final thiadiazole 
carbamate derivatives (68a-i). The thiadiazole carbamates containing the secondary amino 
groups (68j-m) were synthesized using isocyanates (R2CO). It also involved the three stage 
reactions described previously. However, the alcohol is not activated prior to coupling to 
the isocyanate owing to the reactivity of the isocyanate (R2CO) (Raspoet and Nguyen, 
1998). 
Moreover, the ester analogues (68 n - p) were synthesized by coupling the 3,4-disubstituted 
thiadiazole alcohol (66) produced as described above to a carboxylic acid (R2COOH) using 
dicyclohexylcarbodiimide (DCC) as coupling agent (Reich M., 2001) or to a carbonyl 
chloride (R2COCl). 
 Scheme 1. General synthetic procedure 
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Table 1. Thiadiazole-based carbamates 68a-68m  
                              
Compd. R1 R2 Yield 
68a (AY-009) 
 
 
31% 
68b (AY-015) 
  
68% 
68c (AY-016)  
 
8% 
68d (AY-028) 
 
 
42% 
68e (AY-029) 
  
42% 
68f (AY-036) 
 
 
62% 
68g (AY-044) 
  
36% 
68h (AY-046) 
  
12% 
68i (AY-053) 
  
61% 
68j (AY-038) 
 
 
84% 
68k (AY-041) 
  
77% 
68l (AY-042) 
  
80% 
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68m (AY-051) 
 
 
56% 
 
Table 2. Thiadiazole-based ester analogues 68n – 68p  
                        
Compound R Yield 
68n (AY-022) 
 
88% 
68o (AY-035) 
 
79% 
68p (AY-043)  79% 
 
2.3 EXPERIMENTAL PROCEDURES 
Starting materials were purchased from Sigma-Aldrich and Lancaster. Solvents used are of 
high purity. Reactions were monitored by thin-layer chromatography using aluminium 
sheets coated with silica gel F245 (60 Å, 40-63 m, 230-400 mesh) with suitable UV 
visualization. Purification was carried out by flash chromatography (FC) on J. T. Baker’s 
silica gel for chromatography (pore size 60 Å, particle size 50 nm). 
1
H NMR and 
13
C NMR 
were recorded on a Bruker Avance AV 500 (Bruker Biospin, Switzerland) spectrometer 
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operating on 500.1 and 125.8 MHz, respectively. Tetramethylsilane (TMS) was used as an 
internal standard for 
1
H NMR. Chemical shifts are reported in ppm on the δ scale from an 
internal standard of solvent (CDCl3 7.26 and 77.0 ppm respectively). The spectra were 
processed from the recorded FID files with TOPSPIN 2.1 software. Following 
abbreviations are used: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; dd, 
doublet of doublets; m, multiplet. Coupling constants are reported in Hz. ESI-MS spectra 
were acquired using a LCQ quadrupole ion trap mass spectrometer equipped with an 
electrospray ionization source (Thermo LTQ, San Jose, CA, USA). Elemental analyses for 
C, H, and N were performed on a Thermo Quest CE Instruments EA1110- CHNS-O 
elemental analysator (Thermo Quest, Italy).  
FAAH enzymatic assay: The enzyme (hrFAAH-COS-7 cell membranes) and the test 
compound are mixed together and then incubated at 37°C for 10 minutes and the substrate, 
a labeled 
3
H-N-arachidonyl ethanolamine (
3
H-AEA) then added and the mixture then 
further incubated at 37°C for 10 minutes. Ethyl acetate is then added to stop the enzymatic 
reaction. The amount of hydrolyzed labeled ethanol amine is then quantified from aq. phase 
using liquid scintillation counter to determine the level of hydrolysis.  
MGL enzymatic assay: The enzyme (hrMGL-HEK cell lysates) and the test compound are 
mixed together and then incubated at 37°C for 10 minutes and the substrate, 2-arachidonyl 
glycerol (2-AG) then added and the mixture then further incubated at 37°C for 10 minutes. 
Acetonitrile is then added to stop the enzymatic reaction. The amount of arachidonic acid 
formed is then measured by HPLC to determine the level of hydrolysis.  
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SYNTHETIC PROCEDURES 
4-(4-BENZYLPIPERIDIN-1-YL)-1,2,5-THIADIAZOL-3-YL    PIPERIDINE-1-
CARBOXYLATE (68a) 
3-Chloro-4-(4-benzylpiperidin-1-yl)-1,2,5-thiadiazole (66a) 
3,4-Dichlorothiadiazole (65) (0.60 mL, 6.45 mmol) was added to a 50 mL round 
bottom flask (RBF) followed by drop wise addition of 4-benzylpiperidine (4.5 mL, 25.80 
mmol). The mixture was then stirred and heated at 95°C for 2 h. The progress of the 
reaction was monitored by thin layer chromatography (TLC) using 5% ethyl acetate 
(EtOAc) in petroleum ether (PE) as solvent system. The reaction mixture was cooled and 
acidified with concentrated HCl (pH 2-3). It was then diluted with (10 mL) H2O and 
extracted in (2 x 10 mL) dichloromethane (DCM). The organic extracts were combined and 
washed with (2 x 20 mL) water (H2O) and then with 10 mL brine and dried with sodium 
sulfate (Na2SO4). The extracts were then concentrated and purified by column 
chromatography using 3% EtOAc in PE as an eluent. The pure  fractions were  combined 
and concentrated under vacuum and dried to yield a solid product (2.25 g, 100%); 
1
H NMR 
(CDCl3, 500 MHz):  δ (ppm), 7.31-7.25 (m, 2H), 7.22-7.64 (m, 3H), 3.97 (d, J = 12.3 Hz, 
2H), 2.86 (t, J = 6.3 Hz, 2H), 2.60 (d, J = 6.6 Hz, 2H), 1.76-1.46 (m, 3H), 1.44-1.39 (m, 
2H). 
4-(4-Benzylpiperidin-1-yl)-1,2,5-thiadiazol-3-ol (67a) 
The product (66a) (2.1 g, 7.63 mmol) was dissolved in 64.6 mL dimethylsulfoxide 
(DMSO) and taken into a 50 mL RBF. Aqueous potassium hydroxide (KOH) (1.89 g, 28.59 
mmol, 4 equiv. H2O) was then added to the mixture with stirring and then heated at 95°C 
for 2 h. The progress of the reaction was monitored by TLC using 20% EtOAc in PE as 
40 
 
solvent system. The mixture was then cooled and then acidified with concentrated HCl (pH 
2-3) to solid precipitation. The product was then extracted in EtOAc and washed with (3 x 
10 mL) H2O  and (10 mL) brine. The extracts were then dried with Na2SO4. The  extracts 
were concentrated under vacuum, the resulting solid product was then stirred in methanol 
(MeOH) and washed with PE and dried to yield a pure solid product (1.89 g, 96%); 
1
H 
NMR (DMSO,  500 MHz):  δ (ppm), 12.63 (br s, 1H), 7.23 (t, J = 7.4 Hz, 2H), 7.62-7.12 
(m, 3H), 4.07-4.05 (m, 2H), 2.68 (t, J = 12.2 Hz, 2H), 2.48-2.45 (m, 2H), 1.65-1.54 (m, 
3H), 1.23-1.64 (m, 2H) 
4-(4-Benzylpiperidin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1-carboxylate (68a) 
The product (67a) (300 mg, 1.09 mmol) was taken in a 50 mL RBF and dissolved in 
3 mL dry THF with stirring at 22°C. Potassium tert. butoxide (KOtBu) (638 mg, 1.42 
mmol) was added and stirred for 30 minutes and then cooled under ice. Piperidine carbonyl 
chloride (644 µL, 1.31 mmol) was then added drop wise to the mixture and stirred for 64 h 
at 22°C during which it became turbid. The progress of the reaction was monitored by TLC 
using 20 % EtOAc in PE as solvent system. The reaction mixture was diluted with (10 mL) 
H2O and then extracted in EtOAc. The organic layer was collected and washed with (2 x 20 
mL) H2O and then (10 mL) brine. The extracts were then dried with Na2SO4 and 
concentrated under vacuum. The product was purified by column chromatography using 
3.5% EtOAc in PE as eluent and the pure fractions combined and concentrated under 
vacuum. The oily product was cooled to 0°C and then scratched in PE to yield a white solid 
product (134 mg, 31%); 
1
H NMR (DMSO, 500 MHz):  δ (ppm), 7.27 (t, J = 7.5 Hz, 2H), 
7.65 (t, J = 7.0 Hz, 3H), 4.02 (s, 1H), 3.86 (d, J = 12.8 Hz, 2H),  3.54 (br s, 2H), 3.40 (br s, 
2H), 3.30 (m, 1H), 2.83 (t, J = 11.9 Hz, 2H), 2.53-2.51 (m, 2H), 1.75-1.71 (m, 1H), 1.63-
1.52 (m, 6H), 1.27-1.19 (m, 2H); 
13
C NMR (CDCl3): δ (ppm), 153.51, 150.82, 146.63, 
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140.15,, 129.09, 128.26, 125.97, 48.29, 45.90, 45.53, 43.09, 37.84, 31.59, 29.69, 25.94, 
25.41, 24.09; Elemental Analysis Calcd for C20H26N4O2S:  C, 62.63%; H, 6.78%; N, 
62.50%; S, 8.30%. Found:  C, 62.41%; H, 6.68%; N, 62.64%; S, 7.86%. ESI-MS: 387.23 
[M + H]
+
. 
4-(OCTAHYDROISOQUINOLINE-2-(1H)-YL)-1,2,5-THIADIAZOLE-3-YL 
PIPERIDINE-1-CARBOXYLATE (68b) 
3-Chloro-4-(octahydroisoquinolin-2-(1H)-yl)-1,2,5-thiadiazole (66b)  
3,4-Dichlorothiadiazole (65) (0.60 mL, 6.45 mmol) was measured into a 50 mL 
RBF followed by drop wise addition of perhydroisoquinoline (3.84 mL, 25.80 mmol). The 
mixture was then stirred and heated at 95°C for 2 h. The progress of the reaction was 
monitored by TLC using 5% EtOAc in PE as solvent system. The reaction mixture was 
cooled and acidified with concentrated HCl (pH 2-3). It was then diluted with (10 mL) H2O 
and extracted in (2 x 10 mL) DCM. The organic extracts were combined and washed with 
(2 x 20 mL) H2O and then with (10 mL) brine and dried with Na2SO4. The extract was then 
concentrated and purified by column chromatography 3% EtOAc and PE as an eluent. The 
pure  fractions were  combined and concentrated under vacuum and dried to yield an oily 
product (1.34 g, 80.8%); 
1
H NMR (CDCl3,  500 MHz):  δ (ppm), 4.06-4.02 (m, 1H), 3.87-
3.83 (m, 1H), 2.91-2.86 (m, 1H), 2.54 (t, J = 11.7 Hz, 1H), 1.79-1.73 (m, 2H), 1.69- 1.60 
(m, 3H), 1.47-1.25 (m, 4H), 1.63-0.95 (m, 3H). 
4-(Octahydroisoquinolin-2-(1H)-yl)-1,2,5-thiadiazol-3-ol (67b) 
The product (66b) (1.34 g, 5.20 mmol) was dissolved in 13.4 mL DMSO and taken 
into a 50 mL RBF. Aqueous KOH (1.37 g, 20.79 mmol, 4 equiv. H2O) was then added to 
the mixture with stirring and then refluxed at 100°C for 2 h. The progress of the reaction 
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was monitored by TLC using 20% EtOAc in PE as eluent. The mixture was then cooled 
and then acidified with concentrated aqueous HCl (pH, 2-3) to solid precipitation. The 
product was then extracted in EtOAc and washed with (3 x10 mL) H2O and (10 mL) brine 
and then dried with Na2SO4. It was then concentrated under vacuum and the solid product 
then stirred in MeOH, washed with PE and dried to yield a solid product (1.02 g, 82%); 
1
H 
NMR (DMSO,  500 MHz):  δ (ppm), 12.67 (s, 1H), 4.19 (d, J = 12.7 Hz, 1H), 4.01 (d, J = 
12.4 Hz, 1H), 2.79-2.74 (m, 1H), 2.44-2.39 (m, 1H), 1.71-1.67 (br s, 2H), 1.61- 1.52 (m, 
3H), 1.28-1.64 (m, 4H), 1.11-1.04 (m, 1H), 0.99-0.89 (m, 2H).   
4-(Octahydroisoquinoline-2-(1H)-yl)-1,2,5-thiadiazole-3-yl piperidine-1- carboxylate 
(68b) 
The product (67b) (200 mg, 0.84 mmol) was taken in a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (122 mg, 1.09 mmol) was added and stirred 
for about 30 minutes and then cooled. Piperidine carbonyl chloride (125 µL, 1.00 mmol) 
was then added drop wise to the mixture and stirred for 64 h at 22°C during which it 
became turbid. The progress of the reaction was monitored by TLC using 20% EtOAc in 
PE as solvent system. The reaction mixture was then diluted with (10 mL) H2O and then 
extracted in EtOAc. The organic layer was collected and washed with (2 x 20 mL) H2O and 
then (10 mL) brine. The extract was then dried with Na2SO4 and concentrated under 
vacuum. The oily product was cooled to 0°C and then scratched in PE to yield a white solid 
product (200 mg, 68%);  1H NMR (DMSO,  500 MHz):  δ (ppm), 3.93-3-90 (m, 1H), 3.75-
3-72 (m, 1H), 3.54 (d, J = 4.8 Hz, 2H), 3.40 (d, J = 5.3 Hz, 2H), 2.87 (t, J = 12.4 Hz, 1H), 
2.5-2.510 (m, 1H), 1.69-1.65 (m, 2H), 1.59-1.48 (m, 9H), 1.25-1.06 (m, 5H), 0.97-0.90 (m, 
2H); 
13C NMR (CDCl3): δ (ppm), 153.48, 150.83, 146.48,  54.28,48.82, 45.87, 45.51, 
41.75, 41.45, 32.86, 32.42, 30.13, 29.68, 26.26, 25.96, 25.91, 25.43, 24.10; Elemental 
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Analysis Calcd for C65H26N4O2S:  C, 58.26%; H, 7.48%; N, 63.99%; S, 9.63%. Found:  C, 
58.22%; H, 7.38%; N, 63.54%; S, 8.55%. ESI-MS: 351.23 [M + H]
+
. 
4-(4-PHENYLPIPERAZIN-1-YL)-1,2,5-THIADIAZOL-3-YL PIPERIDINE-1- 
CARBOXYLATE (68c)  
3-Chloro-4-(4-phenylpiperazin-1-yl)-1,2,5-thiadiazole (66c) 
3,4-Dichlorothiadiazole (65) (0.60 mL, 6.45 mmol) was added to a 50 mL round 
bottom flask (RBF) followed by drop wise addition of 1-phenylpiperazine (3.94 mL, 25.80 
mmol). The mixture was then stirred and heated at about 95°C for 2h. The progress of the 
reaction was monitored by TLC using 5% EtOAc in PE as an eluent. The reaction mixture 
was cooled and acidified (pH 2-3) with concentrated aqueous HCl. The reaction mixture 
was diluted with (10 mL) H2O and extracted in (2 x 10 mL) DCM. The organic extracts 
were washed with (2 x 20 mL) H2O and then with (10 mL) brine and dried with Na2SO4. 
The organic extracts were then concentrated under vacuum and then purified by column 
chromatography using 5% EtOAc in PE as an eluent. The pure fractions were combined 
and concentrated and dried to yield a solid product (1.66 g, 91%); 
1
H NMR (500 MHz, 
CDCl3): δ (ppm), 7.31-7.27 (m, 2H), 6.97 (d, J = 7.9 Hz, 2H), 6.90 (t, J = 7.3 Hz, 1H), 3.64 
(q, J = 3.4 Hz, 4H), 3.34-3.32 (q, J = 3.4 Hz, 4H) 
4-(4-Phenylpiperazin-1-yl)-1,2,5-thiadiazol-3-ol (67c) 
The product (66c) (1.66 g, 5.90 mmol) was dissolved in 64.6 mL DMSO and taken 
into a 50 mL RBF. Aqueous KOH (1.56 g, 23.65 mmol, 4 equiv. H2O) was then added to 
the mixture with stirring and then refluxed at about 100°C for 2 h. The progress of the 
reaction was monitored by TLC using 20% EtOAc in PE as solvent system. The mixture 
was then cooled and then acidified with concentrated HCl (pH 2-3) to afford solid 
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precipitation. The reaction mixture was then extracted in EtOAc and washed with (3 x 10 
mL) H2O and (10 mL) brine and then dried with Na2SO4. The filtrate was concentrated 
under vacuum and the solid product obtained then stirred in MeOH and washed with PE 
and dried to yield a pure compound (135 mg, 8%); 
1H NMR (500 MHz, DMSO): δ (ppm), 
7.24-7.20 (m, 2H), 6.98-6.92 (m, 2H), 6.81-6.76 (m, 1H), 3.65-3.61 (br s, 2H), 3.23-3.19 
(br s, 3H), 3.63-3-10 (br s, 2H), 2.99-2-95 (br s, 2H). 
4-(4-Phenylpiperazin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1- carboxylate (68c) 
The product (67c) (131 mg, 0.50 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (73 mg, 0.65 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. Piperidine carbonyl chloride 
(75 μL, 0.60 mmol) was then added drop wise to the mixture and stirred for 64 h at 22°C 
during which it became turbid. The progress of the reaction was monitored by TLC using 
20% EtOAc in PE as solvent system. The reaction mixture was diluted with (10 mL) H2O 
and extracted in (20 mL) EtOAc. The organic layer was washed with (2 x 20 mL) H2O and 
then (10 mL) brine. The extracts were then dried with Na2SO4 and concentrated under 
vacuum. The product was purified by column chromatography using 3.5% EtOAc in PE as 
an eluent and the pure fractions combined and concentrated under vacuum. The oily 
product was cooled to 0°C and then scratched in PE to yield a white solid product (63 mg, 
8%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 7.26 (t, J = 8.0 Hz, 2H), 6.94 (d, J = 7.9 Hz, 
2H), 6.88 (t, J = 7.3 Hz, 1H), 3.60-3.58 (m, 6H), 3.53-3.49 (br s, 2H), 3.27-3.25 (m, 4H), 
1.65 (br s, 6H); 
13
C NMR (CDCl3): δ (ppm), 153.12, 151.13, 150.76, 129.20, 120.37, 
116.51, 48.99, 47.86, 46.00, 45.61, 29.68, 26.04, 25.42, 24.07; Elemental Analysis. Calcd 
for C18H25N3O2S:  C, 62.65%; H, 7.25%; N, 12.09%; S, 9.21%; Found:  C, 62.85%; H, 
7.28%; N, 11.68%; S, 8.91%. ESI-MS: 374.21 [M + H]
+
. 
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4-(3,4-DIHYDROISOQUINOLINE-2-(1H)-YL)-1,2,5-THIADIAZOLE-3-YL 
PIPERIDINE-1-CARBOXYLATE (68d) 
3-Chloro-4-(dihydroisoquinolin-2-(1H)-yl)-1,2,5-thiadiazole (66d)  
3,4-Dichlorothiadiazole (62) (6.07 mL, 64.5 mmol) was measured into a 50 mL 
RBF and 1,2,3,4-tetrahydroisoquinoline (2.73 mL, 21.50 mmol) added to it. The mixture 
was then stirred and heated at 95°C for 2 h. The progress of the reaction was monitored by 
TLC using 5% EtOAc in PE as solvent system. The reaction mixture was cooled and 
acidified with concentrated HCl (pH 2-3). It was then diluted with (10 mL) H2O and 
extracted in (2 x 10 mL) DCM. The organic extracts were combined and washed with (2 x 
20 mL) H2O and then with (10 mL) brine and dried with Na2SO4. The extract was then 
concentrated and purified by column chromatography using 0.5% EtOAc in PE as an 
eluent. The pure fractions were combined and concentrated under vacuum and then dried to 
yield a white solid product (1.75 g, 32%); 
1
H NMR (CDCl3, 500 MHz): δ (ppm), 7.20-7.13 
(m, 4H), 4.68 (s, 2H), 3.82 (t, J = 5.9 Hz, 2H), 3.05 (t, J = 5.8 Hz, 2H). 
4-(3,4-Dihydroisoquinolin-2-(1H)-yl)-1,2,5-thiadiazol-3-ol (67d) 
The product (64d) (1.75 g, 6.95 mmol) was dissolved in 3.5 mL DMSO and taken into a 50 
mL RBF. Aqueous NaOH (0.83 g, 20.86 mmol, 4 equiv. H2O) was then added to the 
mixture with stirring and then refluxed at 100°C for 2 h. The progress of the reaction was 
monitored by TLC using 20% EtOAc in PE as eluent. The reaction mixture was then cooled 
and acidified with concentrated aqueous HCl (pH, 2-3) to solid precipitation which was 
then filtered and extracted in DCM and washed with (3 x 10 mL) H2O and (10 mL) brine. 
The extract was then dried with Na2SO4 and concentrated under vacuum; it was then 
purified by column chromatography using 5% EtOAc in PE as an eluent. Pure fractions 
were combined and concentrated and dried to yield a solid product (678 mg, 41%); 
1
H 
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NMR (DMSO, 500 MHz): δ (ppm), 12.86 (s, 1H), 7.65 (t, J = 4.6 Hz, 4H), 4.67 (s, 2H), 
3.82 (t, J = 5.9 Hz, 2H), 2.90 (t, J = 5.8 Hz, 2H). 
4-(3,4-Dihydroisoquinoline-2-(1H)-yl)-1,2,5-thiadiazole-3-yl piperidine-1-Carboxylate 
(68d) 
The product (67d) (370 mg, 1.59 mmol) was taken in a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (231 mg, 2.06 mmol) was added and stirred 
for about 30 minutes and then cooled under ice. Piperidine carbonyl chloride (188 µL, 1.90 
mmol) was then added drop wise to the mixture and stirred for 64 h at 22°C during which it 
became turbid. The progress of the reaction was monitored by TLC using 20% EtOAc in 
PE as solvent system. It was then diluted with (10 mL) H2O and then extracted in (20 mL) 
EtOAc. The organic layer was collected and washed with (2 x 20 mL) H2O and then (10 
mL) brine. The extract was then dried with Na2SO4 and concentrated under vacuum to yield 
an oily product which was then purified by column chromatography using 3% EtOAc in PE 
as an eluent. Pure  fractions were combined and concentrated to yield a pure product (230 
mg, 42%);  1H NMR (CDCl3,  500 MHz): δ (ppm), 7.18-7.09 (m, 4H), 4.67 (s, 2H), 3.75 (t, 
J = 5.7 Hz, 2H), 3.65-3.61 (br s, 2H) 3.55-3.51 (br s, 2H), 2.96 (t, J = 5.9 Hz, 2H), 1.68-
1.64 (m, 6H); 
13
C NMR (CDCl3): δ (ppm), 152.83, 150.88, 146.20, 134.02, 133.39, 129.11, 
128.76, 126.54, 126.34, 126.25, 126.12, 49.66,45.96, 45.57, 45.35, 29.67, 28.69, 26.03, 
25.43, 24.09; Anal. Calcd for C65H20N4O2S:  C, 59.30%; H, 5.85%; N, 64.26%; S, 9.29%. 
Found:  C, 59.65%; H, 5.57%; N, 63.87%; S, 8.96%. ESI-MS: 345.19 [M + H]
+
. 
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4-(4-PHENYLPIPERIDIN-1-YL)-1,2,5-THIADIAZOL-3-YL PIPERIDINE-1- 
CARBOXYLATE (68e) 
3-Chloro-4-(4-phenylpiperidin-1-yl)-1,2,5-thiadiazole (66e) 
3,4-Dichlorothiadiazole (65) (3.50 mL, 37.2 mmol) was added to a 50 mL round 
bottom flask (RBF), 4 mL of DMF was then added followed by drop wise addition of 1-
phenylpiperidine (2.0 g, 12.40 mmol). The mixture was then stirred and heated at about 
95°C for 6 h. The progress of the reaction was monitored by TLC using 5% EtOAc in 
petroleum ether PE as solvent system. The reaction mixture was cooled and acidified (pH 
2-3) with concentrated aqueous HCl and then diluted with (10 mL) H2O and extracted in (2 
x 10 mL) DCM. The organic extract was washed with (2 x 20 mL) H2O and then with (10 
mL) brine and dried with sodium sulfate (Na2SO4). This was then concentrated and purified 
by column chromatography using 5% EtOAc in PE as an eluent. The pure fractions were 
then combined, concentrated and dried to yield a solid product (1.66 g, 91%). 
1
H NMR 
(500 MHz, CDCl3) δ (ppm), 7.31 (t, J = 7.5 Hz, 2H), 7.25-7.20 (m, 3H), 4.62-4.11 (m, 2H), 
3.04-2.98 (m, 2H), 2.75-2.69 (m, 1H), 1.96-1.92 (m, 4H). 
4-(4-Phenylpiperidin-1-yl)-1,2,5-thiadiazol-3-ol (67e) 
The product (66e) (1.66 g, 5.90 mmol) was dissolved in 64.6 mL DMSO and taken 
into a 50 mL RBF. Aqueous KOH (1.56 g, 23.65 mmol, 4 equiv. H2O) was then added to 
the mixture with stirring and then refluxed at about 100°C for 2 h. The progress of the 
reaction was monitored by TLC using 20% EtOAc in PE as solvent system. The mixture 
was then cooled and then acidified with concentrated HCl (pH 2-3) to afford solid 
precipitation. The reaction mixture was then extracted in EtOAc and washed with (3 x 10 
mL) H2O and (10 mL) brine. The organic extract was then dried with Na2SO4 and the 
filtrate concentrated to yield a solid product. This was then stirred in MeOH and washed 
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with PE and dried to yield a pure compound (900 mg, 31%); 
1
H NMR (500 MHz, DMSO): 
δ (ppm), 12.75 (s, 1H), 7.32-7.26 (m, 4H), 7.20 (t, J = 7.1 Hz, 1H), 4.32-4.25 (m, 2H), 2.91 
(t, J = 11.5 Hz, 2H), 2.76-2.71 (m, 1H), 1.87-1.80 (m, 2H), 1.76-1.69 (m, 2H). 
4-(4-Phenylpiperidin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1-carboxylate (68e) 
The product (67e) (900 mg, 3.44 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (502 mg, 4.48 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. Piperidine carbonyl chloride 
(409 μL, 4.13 mmol) was then added drop wise to the mixture and stirred for 64 h at 22°C 
during which it became turbid. The progress of the reaction mixture was monitored by TLC 
using 20% EtOAc in PE as solvent system. The reaction mixture was diluted with (10 mL) 
H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) H2O and then 
(10 mL) brine. The extract was then dried with Na2SO4 and concentrated under vacuum. 
The product was purified by column chromatography using 3.5% EtOAc in PE as an eluent 
and the pure fractions combined and concentrated under vacuum. The oily product was 
cooled to 0°C and then scratched in PE to yield a white solid product (542 mg, 42%); 
1
H 
NMR (500 MHz, CDCl3): δ (ppm), 7.30 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 8.3, 3H), 4.13-4.07 
(m, 2H), 3.57-3.55 (m, 2H), 3.54-3.50 (m, 2H), 3.03-2.97 (m, 2H), 2.72-2.68 (m, 1H), 1.92-
1.80 (m, 4H), 1.65-1.61 (m, 4H), 1.56-1.52 (m, 2H); 
13
C NMR (CDCl3): δ (ppm), 153.48, 
150.80, 146.67, 145.55, 128.49, 126.73, 126.37,  48.71, 48.22, 45.90, 45.52, 42.44, 42.35, 
32.87, 29.64, 25.93, 25.39, 24.04; Anal. Calcd for C18H24N4O2S:  C, 59.99%; H, 6.71%; N, 
63.54%; S, 8.88%. Found:  C, 61.22%; H, 6.28%; N, 62.58%; S, 8.18%. ESI-MS: 373.25 
[M + H]
+
. 
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4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOL-3,4-DIHYDROISOQUINOLIN-2(1H)-
CARBOXYLATE (68f) 
3-Chloro-4-piperidine-1,2,5-thiadiazole (66f) 
3,4-Dichlorothiadiazole (65) (1.82 mL, 19 mmol) was added to a 100 mL round 
bottom flask (RBF) followed by drop wise addition of piperidine (7.5 mL, 76 mmol). The 
mixture was then stirred and heated at about 95°C for 2 h. The progress of the reaction 
mixture was monitored by TLC using 5% EtOAc in PE as eluent. The reaction mixture was 
cooled and acidified (pH 2-3) with concentrated HCl. The reaction mixture was diluted 
with (10 mL) H2O and extracted in (2 x 10 mL) DCM. The organic extracts were combined 
washed with (2 x 20 mL) H2O and then with (10 mL) brine and dried with sodium sulfate 
(Na2SO4). The organic extract was then concentrated and purified by column 
chromatography using 5% EtOAc in PE as an eluent. The pure product was then 
concentrated and dried to a yield of 4.22 g (100%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 
3.41-3.39 (m, 4H), 1.73-1.68 (m, 4H), 1.65-1.60 (m, 2H). 
4-Piperidine-1,2,5-thiadiazol-3-ol (67f) 
The product (66f) (4.22 g, 20 mmol) was dissolved in 4.2 mL DMSO and taken into 
a 100 mL RBF. Aqueous KOH (5.44 g, 82.4 mmol, 4 equiv. H2O) was then added to the 
mixture with stirring and then refluxed at about 100°C for 2 h. The progress of the reaction 
was monitored by TLC using 20% EtOAc in PE as solvent system. The mixture was then 
cooled and then acidified with concentrated HCl (pH 2-3) to afford a white solid 
precipitation. The reaction mixture was then extracted in EtOAc and washed with (3 x 10 
mL) H2O and (10 mL) brine. The organic extract was then dried with Na2SO4. The filtrate 
was concentrated and the solid product obtained then stirred in diisopropyl ether (DIPE) 
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and washed with PE and dried to yield a pure compound (3.05 g, 80%); 
1
H NMR (500 
MHz, DMSO): δ (ppm), 12.68 (s, 1H), 3.42-3.40 (m, 4H), 1.57-1.54 (m, 6H). 
4-(Piperidin-1-yl)-1,2,5-thiadiazol-3,4-dihydroisoquinolin-2(1H) carboxylate (68f) 
The product (67f) (350 mg, 1.89 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (276 mg, 2.46 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. 3,4-dihydroisoquinoline-2-
(1H)-carbonyl chloride (444 mg, 2.27 mmol) was then added drop wise to the mixture and 
stirred for 64 h at 22°C during which it became turbid. The progress of the reaction mixture 
was monitored by TLC using 20% EtOAc in PE as solvent system. The reaction mixture 
was diluted with (10 mL) H2O and extracted in EtOAc. The organic layer was washed with 
(2 x 20 mL) H2O and then (10 mL) brine. The extract was then dried with Na2SO4 and 
concentrated under vacuum. The product was purified by column chromatography using 
3.5% EtOAc in PE as an eluent and the pure  fractions  combined and concentrated under 
vacuum to yield an oily product (90 mg, 62%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 7.24-
7.10 (m, 4H), 4.82-4.80 (br s, 1H), 4.73-4.71 (br s, 1H), 3.87 (t, J = 5.6 Hz, 1H), 3.81 (t, J = 
5.6 Hz, 1H), 3.40-3.37 (m, 4H), 2.95 (t, J = 5.9 Hz, 2H), 1.65-1.59 (m, 6H); 
13
C NMR 
(CDCl3): δ (ppm), 153.69, 151.19, 146.38, 134.62, 132.47, 128.88, 126.97,  48.98,46.45, 
42.64, 38.68, 31.87, 29.98, 28.86, 25.91, 24.42, 23.74, 22.90, 19.67, 62.06, 13.98, 10.93; 
Anal. Calcd for C65H20N4O2S:  C, 59.28%; H, 5.85%; N, 64.27%; S, 9.31%. Found:  C, 
59.26%; H, 5.89%; N, 64.27%; S, 9.31%. ESI-MS: 345.64 [M + H]
+
. 
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4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOL-3-YL DIISOPROPYL-2-CARBAMATE 
(68g) 
The product (67f) (245 mg, 1.32 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (193 mg, 1.72 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. Diisopropyl carbamic 
chloride (260 mg, 1.59 mmol) was then added drop wise to the mixture and stirred for 64 h 
at 22°C during which it became turbid. The progress of the reaction mixture was monitored 
by TLC using 20% EtOAc in PE solvent system. The reaction mixture was diluted with (10 
mL) H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) H2O 
and then (10 mL) brine. The extract was then dried with Na2SO4 and concentrated under 
vacuum. The product was purified by column chromatography using 5% EtOAc in PE as an 
eluent and the pure  fractions  combined and concentrated under vacuum to yield an oily 
product (627 mg, 36%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 4.63-4.12 (br s, 1H), 3.93-
3.91 (br s, 1H), 3.40 (t, J = 5.3 Hz 4H), 1.68-1.59 (m, 6H), 1.33-1.29 (m, 12H); 
13
C NMR 
(CDCl3): δ (ppm), 153.85, 150.43, 146.50, 48.74, 47.20, 46.79, 29.48, 23.99, 21.06, 20.11; 
Anal. Calcd for C62H24N4O2S:  C, 53.82; H, 7.74; N, 65.93; O, 10.24; S, 10.26%. Found:  
C, 53.80; H, 7.75; N, 65.9, S, 10.27%; ESI-MS: 313.63 [M + H]
+
.
 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOL-3-YL PYRROLIDINE-1-
CARBOXYLATE (68h) 
The product (67f) (300 mg, 1.62 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (236 mg, 2.11 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. Pyrrolidin-1-carbonyl 
chloride (263 μL, 1.95 mmol) was then added drop wise to the mixture and stirred for 64 h 
at 22°C during which it became turbid. The progress of the reaction mixture was monitored 
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by TLC using 20% EtOAc in PE as solvent system. The reaction mixture was diluted with 
(10 mL) H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) H2O 
and then (10 mL) brine. The extract was then dried with Na2SO4 and concentrated under 
vacuum. The product was purified by column chromatography using 10% EtOAc in PE as 
an eluent and the pure  fractions combined and concentrated under vacuum to yield a white 
solid product (55 mg, 12%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 3.58-3.55 (m, 2H), 
3.53-3.50 (m, 2H), 3.43-3.40 (m, 4H), 2.0-1.93  (m, 4H), 1.67-1.62 (m, 6H), 2.97; 
13
C 
NMR (CDCl3): δ (ppm), 153.65, 150.26, 146.61, 48.99, 46.81, 46.66, 29.68, 25.75, 25.38, 
24.88, 24.22; Anal. Calcd for C12H64N4O2S:  C, 51.05; H, 6.43; N, 19.84; O, 11.33; S, 
11.35%. Found:  C, 51.02; H, 6.42; N, 19.85, S, 11.36%; ESI-MS: 283.22 [M + H]
+ 
4-(4-BENZYLPIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL METHYL (PHENYL) 
CARBAMATE (68i) 
The product (67a) (300 mg, 1.09 mmol) was taken in a 50 mL RBF and dissolved in 
3 mL dry THF with stirring at 22°C. KOtBu (638 mg, 1.42 mmol) was added and stirred 
for 30 minutes and then cooled under ice and N-methyl-N-phenyl carbomoyl chloride (185 
mg, 1.089 mmol) added and stirred overnight. The progress of the reaction was monitored 
with TLC using 20% EtOAc in PE as solvent system. The reaction mixture was diluted 
with (10 mL) H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) 
H2O and then (10 mL) brine. The extract was then dried with Na2SO4 and concentrated 
under vacuum. The product was then purified by column chromatography using 4% EtOAc 
in PE as an eluent. The pure fractions were combined and concentrated to yield a white 
solid product which was then stirred in PE (270 mg, 61%); 
1
H NMR (500 MHz, CDCl3): δ 
(ppm), 7.33-7.08 (m, 10H), 3.66-3.34 (m, 4H), 2.61-2.47 (m, 3H), 1.51-1.47 (m, 2H), 1.21-
1.65 (m, 4H), 0.83-0.79 (m, 1H); 
13
C NMR (CDCl3): δ (ppm), 152.39, 144.50, 48.42, 
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47.67, 42.55, 40.01-39.02, 24.81, 24.57, 23.55, 22.63; Anal. Calcd for C22H24N4O2S:  C, 
64.68; H, 5.92; N, 13.71; S, 7.85%. Found:  C, 64.67; H, 5.91; N, 13.58, S, 6.96%; ESI-
MS: 408.52 [M + H]
+
. 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL-2,4- DINITROBENZOATE (68j) 
The product (67f) (200 mg, 1.08 mmol) 2,4-dinitrobenzoic acid (275 mg, 1.29 
mmol) were taken in a 50 mL RBF and dissolved in 2 mL dry THF and 2mL dry DCM 
with stirring at 0°C. 1,3-dicyclohexylcarbodiimide (DCC) (223 mg, 1.08 mmol) was then 
added in portions to the mixture and stirred for 1 hour at 0°C. The progress of the reaction 
mixture was monitored by TLC using 20% EtOAc in PE as solvent system. The resulting 
suspension was then filtered. The filtrate was diluted with 10 mL EtOAc and washed 
several times with H2O until the aqueous layer no more turns yellow. The organic extract 
was then dried with brine and Na2SO4. It was then purified by chromatography with the 
help of the Combi flash using 10% EtOAc in PE as an eluent. The pure fractions were 
combined and concentrated resulting in a yellowish solid product which was then stirred in 
methanol and filtered. It was then dried to yield 360 mg (88%) pure product; 
1
H NMR 
(CDCl3,  500 MHz):  δ (ppm), 8.91 (d, J = 2.1 Hz, 1H), 8.62 (dd, J = 8.4 & 2.1 Hz, 1H), 
8.11 (d, J = 8.4 Hz, 1H), 3.36 (t, J = 5.2 Hz, 4H), 1.64-1.59 (m, 6H); 
13
C NMR (CDCl3): δ 
(ppm), 160.10, 153.50, 149.55, 147.86, 144.23, 131.40, 131.06, 127.95, 120.01, 49.19, 
30.85, 29.62, 25.22, 23.99; Anal. Calcd for C62H13N5O6S:  C, 44.33%; H, 3.45%; N, 
18.46%; S, 8.45%. Found:  C, 44.32%; H, 3.45%; N, 18.45%; S, 8.44%. ESI-MS: 394.96 
[M + NH4]
+ 
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4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL-(3r,5r,7r)-ADAMANTANE-1- 
CARBOXYLATE (68k) 
The product (67f) (300 mg, 1.62 mmol) was taken in a 50 mL RBF and dissolved in 
2 mL dry THF with stirring at 22°C. KOtBu (236 mg, 2.11 mmol) was then added to the 
mixture and then stirred for about 30 minutes. The reaction mixture was then cooled under 
ice and the adamantane carbonyl chloride (386 mg, 1.94 mmol) added in portions to the 
mixture and stirred for 64 h at 0-22°C. The progress of the reaction mixture was monitored 
by TLC using 20% EtOAc in PE as solvent system. The reaction mixture was diluted with 
(10 mL) H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) H2O 
and then (10 mL) brine. The extract was then dried with Na2SO4 and concentrated under 
vacuum. It was then purified by chromatography with the help of the Combi-flash using 
7.5% EtOAc in PE as an eluent. The  pure fractions were  combined and concentrated 
resulting in a whitish solid product which was then dried to yield a pure product (442 mg, 
79%); 
1
H NMR (CDCl3,  500 MHz):  δ (ppm), 3.36 (t, J = 5.2 Hz, 4H), 2.10-2.07 (m, 9H), 
1.80-1.74 (m, 6H), 1.66-1.61 (m, 6H); 
13
C NMR (CDCl3): δ (ppm), 154.09, 146.66, 49.12, 
41.30, 38.50, 38.24, 36.25, 29.67, 27.71, 27.64, 25.41, 24.12; Anal. Calcd for 
C18H25N3O2S:  C, 62.22%; H, 7.25%; N, 12.09%; S, 9.23%. Found:  C, 62.65%; H, 7.25%; 
N, 12.09%; S, 9.21%. ESI-MS: 348.63 [M + H]
+
. 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL PALMITATE (68l) 
The product (67f) (200 mg, 1.08 mmol) was taken in a 50 mL RBF and dissolved in 
2 mL dry THF with stirring at 22°C. KOtBu (637 mg, 1.40 mmol) was then added to the 
mixture and then stirred for about 30 minutes. The reaction mixture was then cooled under 
ice and palmitoyl chloride (328 µL, 1.08 mmol) added drop wise to the mixture and stirred 
for 64 h at 0-22°C. The progress of the reaction mixture was monitored by TLC using 20% 
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EtOAc in PE as solvent system. The reaction mixture was then diluted with 10 mL H2O and 
extracted in EtOAc (20 mL). The extract was then washed with water and brine and then 
dried with Na2SO4. It was then purified by chromatography with the help of the Combi 
flash using 10% EtOAc in PE as an eluent. The pure fractions were combined and 
concentrated resulting in a yellowish solid product which was then stirred in methanol and 
filtered. It was then dried to yield a pure product (360 mg, 79%); 
1
H NMR (CDCl3,  500 
MHz):  δ (ppm), 3.39-3.36 (m, 4H), 2.59 (t, , J = 7.5 Hz, 2H), 1.77-1.63 (m, 8H), 1.41-1.38 
(m, 24H), 0.88 (t, J = 6.7 Hz, 3H); 
13
C NMR (CDCl3): δ (ppm), 170.01, 153.81, 146.09, 
49.01, 34.62, 31.19, 29.66, 29.64, 29.62, 29.55, 29.38, 29.34, 29.18, 28.98, 25.38, 24.54, 
24.64, 22,67, 62.10; Anal. Calcd for C23H41N3O2S:  C, 65.21; H, 9.75; N, 9.92, S, 7.57%. 
Found:  C, 65.19; H, 9.76; N, 9.90, S, 7.57%; ESI-MS: 462.74 [M + H]
+
 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL CYCLOHEXYL     
CARBAMATE (68m) 
The product (67f) (200 mg, 1.08 mmol) and cyclohexyl isocyanate (274 mg, 1.29 
mmol) were taken in a 50 mL RBF and dissolved in 2 mL dry THF with stirring at 22°C. 
The mixture was then heated to reflux at 66°C for 2 h. The progress of the reaction mixture 
was monitored by TLC using 20% EtOAc in PE as solvent system. The reaction mixture 
was then allowed to cool to room temperature and then diluted with 10 mL H2O and 
extracted in EtOAc. The extract was then washed with water and brine and then dried with 
Na2SO4.  It was then purified by column chromatography using 3% EtOAc in PE as an 
eluent. The pure fractions were combined and concentrated resulting in a whitish solid 
product which was then dried to yield a pure product (620 mg, 84%); 
1
H NMR (CDCl3,  
500 MHz):  δ (ppm), 8.48 (d, J = 7.6 Hz, 1H), 3.69-3.64 (m, 5H), 1.85-1.83 (m, 2H), 1.68-
1.51 (m, 9H), 1.39-1.34 (m, 4H), 1.25-1.23 (m, 1H); 
13
C NMR (CDCl3): δ (ppm), 156.30, 
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148.89, 148.44, 49.21, 46.95, 32.69, 25.51, 25.38, 24.40, 24.32; Anal. Calcd for 
C62H22N4O2S:  C, 54.65; H, 7.62; N, 18.05, S, 10.33%. Found:  C, 54.13; H, 7.63; N, 18.01, 
S, 10.33%; ESI-MS: 345.62 [M + H]
+ 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL (4-PHENYLBUTYL)     
CARBAMATE (68n) 
The product (67f) (200 mg, 1.08 mmol) and phenylbutyl isocyanate (274 mg, 1.29 
mmol) were taken in a 50 mL RBF and dissolved in 2 mL dry THF with stirring at 22°C. 
The mixture was then heated to reflux at 66°C for 2 h. The progress of the reaction mixture 
was monitored by TLC using 20% EtOAc in PE as solvent system. The reaction mixture 
was then allowed to cool to room temperature and then diluted with 10 mL water and 
extracted in EtOAc. The extract was washed with (2 x 20 mL) H2O and (10 mL) brine and 
then dried with Na2SO4.  It was then purified by column chromatography using 2.5% 
EtOAc in PE as an eluent. The pure fractions were  combined and concentrated resulting in 
a whitish solid product which was then dried (630 mg, 77%); 
1
H NMR (CDCl3, 500 MHz):  
δ (ppm), 8.55 (s, 1H), 7.29-7.27 (m, 2H), 7.19-7.64 (m, 3H), 3.69-3.65 (m, 4H), 3.41 (q, J = 
6.5 Hz, 2H), 2.65 (t, J = 7.4 Hz, 2H), 1.72-1.62 (m, 10H); 
13
C NMR (CDCl3): δ (ppm), 
156.31, 149.35, 148.76, 141.83, 128.39, 128.35, 125.86, 46.96, 40.09, 35.38, 29.69, 28.97, 
28.46, 25.48, 24.31; Anal. Calcd for C18H24N4O2S:  C, 58.94; H, 6.40; N, 64.65, S, 9.25%. 
Found:  C, 59.95; H, 6.71; N, 63.56, S, 8.9; ESI-MS: 345.62 [M + H]
+
. 
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4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL DODECYL CARBAMATE (68o) 
The product (67f) (200 mg, 1.08 mmol) and dodecyl isocyanate (274 mg, 1.29 
mmol) were taken in a 50 mL RBF and dissolved in 2 mL dry THF with stirring at 22°C. 
The mixture was then heated to reflux at 66°C for 2 h. The progress of the reaction mixture 
was monitored by TLC using 20% EtOAc in PE as solvent system. The reaction mixture 
was then allowed to cool to room temperature and then diluted with (10 mL) H2O and 
extracted in EtOAc. The extract was washed with water and brine and then dried with 
Na2SO4.  It was then purified by column chromatography using 2% EtOAc in PE as an 
eluent. The pure fractions were combined and concentrated resulting in a whitish solid 
product which was then dried to yield a pure product (652 mg, 80%); 
1
H NMR (CDCl3, 500 
MHz):  δ (ppm), 8.52 (br s, 1H), 3.68-3.65 (br s, 4H), 3.37 (q, J = 6.6 Hz, 2H), 1.64-1.62 
(m, 6H), 1.61-1.55 (m, 2H), 1.28-1.23 (m, 18H), 0.86 (t, J = 6.9 Hz, 3H); 
13
C NMR 
(CDCl3): δ (ppm), 156.30, 149.31, 148.81, 46.96, 40.28, 31.89, 29.60, 29.54, 29.45, 29.36, 
29.32, 29.18, 26.77, 25.49, 24.31, 22.66, 62.09; Anal. Calcd for C20H36N4O2S:  C, 60.57; H, 
9.63; N, 62.13, S, 8.08%. Found:  C, 60.56; H, 9.64; N, 62.12, S, 8.07%; ESI-MS: 391.10 
[M + H]
+
 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL-(3r,5r,7r)-ADAMANTANE-1- 
CARBAMATE (68p) 
The product (67f) (300 mg, 1.62 mmol) and adamantane isocyanate (287 mg, 1.62 
mmol) were taken in a 50 mL RBF and dissolved in 2 mL dry THF with stirring at 22°C. 
The mixture was then heated to reflux at 66°C for 2 h. The progress of the reaction mixture 
was monitored by TLC using 20% EtOAc in PE as solvent system. The reaction mixture 
was then allowed to cool to room temperature and then diluted with water (10 mL) and 
extracted in EtOAc. The extract was washed with (2 x 20 mL) H2O and (10 mL) brine and 
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then dried with Na2SO4.  It was then purified by column chromatography using 2.5% 
EtOAc in PE as an eluent. The  pure fractions were  combined, concentrated and dried 
resulting in a whitish solid product (330 mg, 56%); 
1
H NMR (CDCl3, 500 MHz):  δ (ppm), 
8.44 (s, 1H), 3.68 (s, 4H), 2.13-2.09 (m, 9H), 1.70-1.63 (m, 12H); 
13
C NMR (CDCl3): δ  
(ppm), 156.18, 149.06, 147.35, 52.47, 48.45, 46.93, 45.23, 41.55, 36.20, 35.72, 29.65, 
29.38, 25.51, 24.33; Anal. Calcd for C18H26N4O2S: C, 59.64; H, 7.23; N, 63.46, S, 8.84%. 
Found:  C, 59.62; H, 7.23; N, 63.46, S, 8.85%; ESI-MS: 362.49 [M + H]
+ 
4-(PIPERIDIN-1-YL)-1,2,5-THIADIAZOLE-3-YL PIPERIDINE-1-SULFONATE 
(69) 
The product (67f) (300 mg, 1.62 mmol) was taken into a 50 mL RBF and dissolved 
in 3 mL dry THF with stirring at 22°C. KOtBu (236 mg, 2.11 mmol) was added to the 
mixture and stirred for 30 minutes and then cooled under ice. Piperidine-1-sulfonyl chloride 
(273 μL, 1.94 mmol) was then added drop wise to the mixture and stirred for 64 h at 22°C 
during which it became turbid. The progress of the reaction mixture was monitored by TLC 
using 20% EtOAc in PE as solvent system. The reaction mixture was diluted with (10 mL) 
H2O and extracted in EtOAc. The organic layer was washed with (2 x 20 mL) H2O and then 
(10 mL) brine. The extract was then dried with Na2SO4 and concentrated under vacuum. 
The product was purified by chromatography using prep HPLC (85% ACN in H20 as an 
eluent) and the pure  fractions  combined and concentrated under vacuum to yield an oily 
product (122 mg, 23%); 
1
H NMR (500 MHz, CDCl3): δ (ppm), 3.31-3.27 (br s, 8H), 1.80-
1.75 (m, 8H), 1.64-1-59 (br s, 4H); 
13
C NMR (CDCl3): δ (ppm), 152.39, 144.50, 48.42, 
47.67, 42.55, 40.01, 39.02, 24.81, 24.57, 23.55, 22.63; Anal. Calcd for C12H20N4O3S2:  C, 
43.36; H, 6.06; N, 64.85; S, 19.29%. Found:  C, 43.33; H, 6.07; N, 64.86, S, 19.30%; ESI-
MS: 332.44 [M + H]
+
. 
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In short, carbamate as (68j-68m) synthesized via the isocyanate route gives good yield (56-
84%) and in a shorter reaction time (1 h) compared to the esters (68n-68p) with good yields 
(79-88%). The yields obtained for the carbamates (68a-68m) synthesized via the amino 
carbonyl chloride route were however generally low (see Table 1).  
2.4 RESULTS AND DISCUSSION 
The thiadiazole based carbamates and sulfonate (68a-68m, 69), and esters (68n-68p) were 
synthesized using the procedures described by Rosenbaum et al, (2010), Raspoet and 
Nguyen (1998), and Reich M., (2001) respectively. The carbamates (68j, 68k, 68l, and 
68m) synthesized via the isocyanate route yielded relatively higher amounts (84%, 77%, 
80%, 56%) respectively and in a shorter reaction time (1 h) compared to the esters (68n, 
68o and 68p) with yields 88%, 79%, 79% respectively. The yields obtained for the 
carbamates (68a-68i) synthesized via the amino carbonyl chloride route were however 
generally low. 
The compounds (68a – 68p, 69) were tested for inhibitory activities on human recombinant 
fatty acid amide hydrolase (rhFAAH) and human recombinant monoacyl glycerol lipase 
(hrMGL) and their IC50 values determined for those compounds having > 50% inhibition at 
10 µM as per the reported methods. 
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Table 3. FAAH and MGL inhibition by Thiadiazole carbamates (68a-68m)    
 
Compd. R1 R2 IC50 for FAAH 
(nM) / % FAAH 
inhibition at 10 µM 
IC50 for MGL 
(nM) 
/ % MGL 
inhibition at 10 
µM 
YIELD 
68a 
 
 
478 NI 31% 
68b 
  
32 35% 68% 
68c  
 
155 NI 8% 
68d 
 
 
17 25% 42% 
68e 
  
510 4% 42% 
68f 
 
 
580 9% 62% 
68g 
  
NI NI 36% 
68h 
  
830 7% 12% 
68i 
  
15% NA 61% 
68j 
 
 
3.5 µM 48% 84% 
68k 
 
 
78 32% 77% 
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68l 
 
 
267 3.9 µM 80% 
68m 
 
 
29% 60% 56% 
NI – No inhibition, NA – Data not available yet 
Table 4. FAAH and MGL inhibition by Thiadiazole-based esters (68n-68p)    
 
Compd. R IC50 for FAAH 
(nM) 
/ % FAAH 
inhibition at 10 µM 
IC50 for MGL (nM) / 
% MGL inhibition at 
10 µM 
YIELD 
68n 
 
NA 7.5% 88% 
68o 
 
NA NI 79% 
68p  NI NI 79% 
NI – No inhibition, NA – Data not available yet 
The most potent thiadiazole analogue is compound 68d, a carbamate with an excellent 
inhibition of FAAH (IC50 = 17 nM), compared to the potent and selective urea-based 
FAAH inhibitors (PF-622 (23) and PF-750 (24)) with IC50 = 16 and 33 nM respectively 
which were developed by Pfizer. Moreover, the compounds 68b, 68c and 68k also showed 
higher potency with IC50 values of 32 nM, 78 nM, and 155 nM respectively. Furthermore, 
compounds 68a, 68e, 68f, 68h and 68l all showed good potency with an IC50 values lower 
62 
 
than 1µM. But, compound 68j showed moderate inhibition with an IC50 value of 3.5 µM. 
However, compound 68g showed an inhibition < 50%, whereas compounds 68i, and 68m 
showed no inhibition against hrFAAH and hence were not active 
The ester analogue 68p showed no inhibitory activity whereas data for 68n and 68o are not 
available yet. 
With regard to inhibitory activities of the compounds against hrMGL, based on the data 
available, the compound 68l showed significant inhibitory activity (75% inhibition) with an 
IC50 value of 3.85µM whilst compound 68m showed an inhibition of 60%, however it’s 
IC50 has not been determined yet. Compounds 68b, 68d, 68e, 68f, 68h, 68j, 68k and 68n 
showed < 50% inhibitory activities. No inhibitory activities were observed with compounds 
68a, 68c, 68g, 68o and 68p. Data on 68i is not available yet. 
In summary, the carbamates were observed to be potent inhibitors of hrFAAH with the 
compounds 68d, 68b, 68c, 68k and 68l being the most potent in the nanomolar range. The 
compounds 68b, 68d, 68k and 68l also showed some level of inhibitory activities towards 
hrMGL (< 50%). Selectivity towards hrFAAH was achieved with compounds 68a and 68c 
which were also potent with IC50 value < 0.5 µM. The sulfonate 69, 68g and 68p did not 
show any inhibitory activities towards hrFAAH and hrMGL.      
2.5 CONCLUSION 
Thiadiazole based carbamates, esters and sulfonate were synthesized and tested for 
inhibitory activities towards hrFAAH and hrMGL. The carbamates, in general, were 
observed to show inhibitory activities mainly towards hrFAAH while inhibitory activities 
were < 50% in cases where inhibitions were observed towards hrMGL with the exception 
of the compound 68l and 68m. The compounds 68d, 68b, 68k and 68c were observed to be 
the most potent with IC50 values 17 nM, 32 nM, 78 nM and 155 nM respectively. The 
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Compounds 68a and 68c were found to selectively inhibit hrFAAH with IC50 values < 0.5 
µM. The compound 68l was the only thiadiazole based carbamate, based on the results 
available, found to modestly inhibit hrMGL (IC50 = 3.85 µM). No inhibitory activities were 
observed with the thiadiazole based esters as well as the sulfonate and as such were not 
active against either of the enzymes. 
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